title: Reversible sudden hearing loss in a chronic hepatitis C patient who achieved a sustained response to antiviral re-treatment.
abstract: We describe the case of a patient with chronic hepatitis C treated with standard and pegylated-interferon (PEG-IFN) alpha and ribavirin. He developed a reversible hearing loss during the first course of PEG-IFN + ribavirin, but achieved sustained viral clearance and biochemical normalization after PEG-IFN + ribavirin re-treatment.
authors: Department Internal Medicine and Hepatology, Second University of Naples, Naples, Italy.
authors: Rosa
authors: R
authors: Zampino
authors: Giuseppe
authors: G
authors: Costa
authors: Mariarosaria
authors: M
authors: Barillari
authors: Luigi Elio
authors: LE
authors: Adinolfi
authors: Aldo
authors: A
authors: Marrone
mesh_terms: D000410:Alanine Transaminase / Q000097:blood; D000740:Anemia / Q000209:etiology; D000998:Antiviral Agents / Q000009:adverse effects* / Q000627:therapeutic use; D015415:Biomarkers; D016903:Drug Monitoring; D057915:Drug Substitution; D004359:Drug Therapy, Combination; D003639:Hearing Loss, Sudden / Q000209:etiology*; D046088:Hearing Loss, Unilateral / Q000209:etiology*; D019698:Hepatitis C, Chronic / Q000097:blood / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000009:adverse effects* / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D012254:Ribavirin / Q000627:therapeutic use
chemical_list: D000998:Antiviral Agents; D015415:Biomarkers; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; D000410:Alanine Transaminase; C417083:peginterferon alfa-2b